8 research outputs found
Levels of job commitment in an organizational environment A field study at the Foreign Bank of Algeria
No full textThe job commitment is desireshown by the individual in social interaction in order to achieve the goals of the organisation it has become necessary to state that the organisation\u27s exploitation of job commitment, by adopting its positive aspects and paying attention to its negative goals, may lead to making sound and practical decisions in implementation, in addition to the organisation\u27s understanding of the impact of both informal organisation and functional commitment
La météorologie du sensible chez Nina Bouraoui
No full textNée entre deux cultures, occidentale et orientale, Nina Bouraoui a écrit un journal intime qui lui ressemble. Poupée Bella possède les caractéristiques du journal intime, mais aussi ceux d’un récit autobiographique. Nous avons noté de même quelques traces qui le rattacheraient au témoignage. Ce qui est sûr, c’est son appartenance à la sphère du « récit de soi », mais encore sa valeur poétique indéniable qui montre la sensibilité de l’auteure et son véritable amour pour l’écriture.Born between two cultures, Western and Eastern, Nina Bouraoui wrote a diary that resembles her. Poupée Bella has the characteristics of a diary, but also those of an autobiographical narrative. We can also find in it some traces of a testimony. What is certain is it belongs to the sphere of “self-narrative”, and it has an undeniable poetic value that shows the sensitivity of the author and her true love for writing
L’écriture du corps et de la mémoire ou le Standard selon Nina Bouraoui
No full textStandard tient une place particulière dans l’œuvre romanesque grandissante de Nina Bouraoui. Après tant de personnages féminins, cette auteure prend le pari d’un point de vue masculin. Elle le fait avec tout ce que cela implique de radical, s’éloignant ainsi de l’image presque stéréotypée de ses précédents personnages. Nous avons opté pour une approche comparatiste qui nous a permis de mettre en perspective les thèmes chers à Bouraoui et d’en dévoiler deux d’entre eux : le corps et l’indécision.Standard holds a special place in Nina Bouraoui’s growing body of fiction. After so many female characters, this author takes the gamble from a male point of view. She does so with all that this implies in terms of radicalism ; moving away from the almost stereotypical image of her previous characters. We have opted for a comparative approach that has allowed us to put into perspective the dedicated themes for Bouraoui and to reveal two of them : the body and indecision.يحتل "النمط" مكانة خاصة في الأعمال الروائية المتنامية لنينا بوراوي، فبعد تقديمها لعدد من الشخصيات النسوية، غامرت هذه المرة بتقديم وجهة نظر ذكورية بكل ما ينطوي عليه ذلك من راديكالية، إذ ابتعدت نوعا ما عن الصور الشبه نمطية لشخصياتها السابقة، وقد اخترنا في هذه الدراسة اعتماد المقارنة التي تسمح لنا باستكشاف الموضوعات الأثيرة عند بوراوي والكشف عن اثنين منها وهما : الجسد والتردّد
Author Correction: Origin and tuning of bandgap in chiral phononic crystals
No full textInternational audienceThere is a mistake in Figure 2 of the paper "Origin and tuning of bandgap in chiral phononic crystals (vol. 7, 272, 2024)". The original figure with a mistake is presented</div
Modulation of COX-2 expression by statins in human monocytic cells
No full textMacrophage cyclooxygenase-2 (COX-2) plays an important role in prostaglandin E2 and thromboxane A2 production. Statins are inhibitors of HMG CoA (3-Hydroxy-3-methylglutaryl coenzyme A) reductases and cholesterol synthesis, which block the expression of several inflammatory proteins independent of their capacity to lower endogenous cholesterol. In the present study, we investigated the effect of simvastatin and mevastatin on COX-2 induction in human monocytic cell line U937 and analyzed the underlying mechanisms. Pretreatment of U937 cells with simvastatin or mevastatin for 24 h resulted in a significant reduction in the lipopolysaccharide (LPS)-dependent induction of prostaglandin E2, thromboxane A2 synthesis, and COX-2 expression. Mevalonate, the direct metabolite of HMG CoA reductase, and farnesyl pyrophosphate and geranylgeranyl-pyrophosphate, intermediates of the mevalonate pathway, significantly reversed the inhibitory effect of statins on COX-2. An inhibitor of geranylgeranyl transferases, GGTI-286 mimicked the effect of statins on COX-2 expression. Cytonecrotic factor-1 increased LPS-dependent expression of COX-2. Treatment of cells with NSC 23766, an inhibitor of Rac, which we demonstrated to block Rac 2 activation, resulted in an inhibition of the LPS-dependent expression of COX-2. Whereas no effect was obtained with RhoA-C blocker, C3 exoenzyme. Gel retardation experiments and NFκB-p65 transcription factor assay showed that simvastatin and NSC 23766 decrease significantly NF-κB complex formation. In macrophages, the antiinflammatory effects of statins are mediated in part through the inhibition of COX-2 and prostanoids. Rac GTPase protein is identified as one of the targets of statins in this regulation. © FASEB.Barbieri SS, 2003, CARDIOVASC RES, V60, P187, DOI 10.1016-S0008-6363(03)00365-1; Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074-jbc.274.11.7545; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074-jbc.274.19.13198; Bishop-Bailey D, 1998, BIOCHEM BIOPH RES CO, V249, P44, DOI 10.1006-bbrc.1998.8966; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172-JCI119603; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724; Chen JC, 2004, EXP CELL RES, V301, P305, DOI 10.1016-j.yexcr.2004.05.039; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172-JCI27540; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126-science.1068711; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161-hc3401.093152; Cipollone F, 2003, CIRCULATION, V107, P1479, DOI 10.1161-01.CIR.0000056530.03783.81; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161-01.ATV.0000133192.39901.be; Corsini Alberto, 2000, Journal of Cardiovascular Pharmacology and Therapeutics, V5, P161, DOI 10.1177-107424840000500304; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016-0005-2760(94)00196-6; Degraeve F, 2001, J BIOL CHEM, V276, P46849, DOI 10.1074-jbc.M104197200; Demasi M, 2003, J BIOL CHEM, V278, P38607, DOI 10.1074-jbc.M305944200; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Doye A, 2002, CELL, V111, P553, DOI 10.1016-S0092-8674(02)01132-7; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126-science.1103333; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161-01.CIR.0000153386.95356.78; Fabre JE, 2001, J CLIN INVEST, V107, P603, DOI 10.1172-JCI10881; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074-jbc.272.21.13484; FitzGerald GA, 2000, ANN MED, V32, P21; FitzGerald GA, 2001, CLIN EXP RHEUMATOL, V19, pS31; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056-NEJMp048288; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073-pnas.0307512101; Gomez-Hernandez A, 2006, J CARDIOVASC PHARM, V47, P60; Gotto Jr AM, 2003, CLIN CARDIOL S1, V26, P21; Grosser N, 2004, FREE RADICAL BIO MED, V37, P2064, DOI 10.1016-j.freeradbiomed.2004.09.009; Grosser N, 2004, BIOCHEM BIOPH RES CO, V325, P871, DOI 10.1016-j.bbrc.2004.10.123; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172-JCI27291; HABIB A, 1993, J BIOL CHEM, V268, P23448; Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016-S0021-9150(01)00547-0; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006-bbrc.1998.8222; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kothapalli D, 2004, J CLIN INVEST, V113, P609, DOI 10.1172-JCI200419097; Laufer S, 2003, CURR OPIN RHEUMATOL, V15, P623, DOI 10.1097-00002281-200309000-00017; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074-jbc.273.37.24266; Liao JK, 2002, INT J CARDIOL, V86, P5, DOI 10.1016-S0167-5273(02)00195-X; Liao J K, 2004, Int J Clin Pract Suppl, P41; Martel-Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016-S0049-0172(03)00134-3; Martin-Ventura JL, 2005, STROKE, V36, P1796, DOI 10.1161-01.STR.0000174289.34110.b0; Miggin SM, 2003, J BIOL CHEM, V278, P6947, DOI 10.1074-jbc.M210637200; Moreau V, 2003, MOL CELL BIOL, V23, P6809, DOI 10.1128-MCB.23.19.6809-6822.2003; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016-S0012-1606(02)00026-0; O'Meara SJ, 2004, BRIT J PHARMACOL, V143, P292, DOI 10.1038-sj.bjp.0705947; O'Meara SJ, 2004, BRIT J PHARMACOL, V143, P318, DOI 10.1038-sj.bjp.0705956; O'Meara SJ, 2005, BIOCHEM J, V386, P177, DOI 10.1042-BJ20041290; Ongini E, 2004, P NATL ACAD SCI USA, V101, P8497, DOI 10.1073-pnas.0401996101; Paramo J. A., 2005, Current Drug Targets - Cardiovascular and Haematological Disorders, V5, P303, DOI 10.2174-1568006054553381; Penglis PS, 2000, J IMMUNOL, V165, P1605; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021-ac00284a003; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038-35070019; Shovman O, 2002, IMMUNOL RES, V25, P271, DOI 10.1385-IR:25:3:271; Smith WL, 1992, AM J PHYSIOL, V263, P181; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074-jbc.275.9.6259; ZHANG SZ, 1990, CELL BIOL TOXICOL, V6, P21927272
A Case of Nail Psoriasis Successfully Treated with Intralesional Methotrexate
No full textFull copyright for enhanced digital
features is owned by the authors. Article full
text
The full text of this article can be found here.
Provide enhanced digital features for this article
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact [email protected].
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as ‘peer reviewed’ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.
Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides
</p
Split-dose menthol-enhanced PEG vs PEG-ascorbic acid for colonoscopy preparation
No full textAIM: To compare the efficacy and palatability of 4 L polyethylene glycol electrolyte (PEG) plus sugar-free menthol candy (PEG + M) vs reduced-volume 2 L ascorbic acid-supplemented PEG (AscPEG). METHODS: In a randomized controlled trial setting, ambulatory patients scheduled for elective colonoscopy were prospectively enrolled. Patients were randomized to receive either PEG + M or AscPEG, both split-dosed with minimal dietary restriction. Palatability was assessed on a linear scale of 1 to 5 (1 = disgusting; 5 = tasty). Quality of preparation was scored by assignment-blinded endoscopists using the modified Aronchick and Ottawa scales. The main outcomes were the palatability and efficacy of the preparation. Secondary outcomes included patient willingness to retake the same preparation again in the future and completion of the prescribed preparation. RESULTS: Overall, 200 patients were enrolled (100 patients per arm). PEG + M was more palatable than AscPEG (76% vs 62%, P = 0.03). Completing the preparation was not different between study groups (91% PEG + M vs 86% AscPEG, P = 0.38) but more patients were willing to retake PEG + M (54% vs 40% respectively, P = 0.047). There was no significant difference between PEG + M vs AscPEG in adequate cleansing on both the modified Aronchick (82% vs 77%, P = 0.31) and the Ottawa scale (85% vs 74%, P = 0.054). However, PEG + M was superior in the left colon on the Ottawa subsegmental score (score 0-2: 94% for PEG + M vs 81% for AscPEG, P = 0.005) and received significantly more excellent ratings than AscPEG on the modified Aronchick scale (61% vs 43%, P = 0.009). Both preparations performed less well in afternoon vs morning examinations (inadequate: 29% vs 15.2%, P = 0.02). CONCLUSION: 4 L PEG plus menthol has better palatability and acceptability than 2 L ascorbic acid-PEG and is associated with a higher rate of excellent preparations; Clinicaltrial.gov identifier: NCT01788709. © The Author(s) 2015
Towards objective endoscopic diagnosis of Barrett's associated early neoplasia using fibre-optic Raman Spectroscopy
No full textThis translational research evaluates a novel, custom-built Raman probe for potential
application as an in vivo diagnostic tool in the oesophagus. Raman spectroscopy (RS) is a
well established analytical technique which is capable of probing the biochemical changes
associated with neoplastic progression in oesophageal tissue. RS relies on measurement of
subtle inelastic scattering signals following monochromatic laser excitation.
Clinical utilisation of RS within hollow organs requires accurate collection and transmission
of signal through fibre-optic cables. This research aims to evaluate the ability of a custom
built fibre-optic Raman probe, in conjunction with multivariate classification models, to
differentiate between benign and neoplastic oesophageal pathologies ex vivo. The need for
spectral stability and reproducibility are addressed, as are difficulties associated with multisystem
reliability. In addition, the biochemical basis of spectral classification is evaluated and
discussed. Cont/d
